Analysis of the Rule of Application of Chinese Patent Medicine Containing Schisandra Chinensis

Tian-yuan LIU, Xiao-yan FANG, Ming BAI, Ming-san MIAO

Abstract


Purpose: In order to analyze the rule of Chinese patent medicine with schisandra fruit, it provides reference for clinical medicine. Methods: With the 2015 edition of the Chinese pharmacopoeia as the data source, the Chinese patent medicines containing schisandra were collected. With Excel 2013 and SPSS Modeler 14.1 statistical software, the collected prescriptions and single traditional Chinese medicines were statistically processed and the association rules were analyzed. Results: Among all prescriptions included in the standard, the top four herbs with the highest cumulative frequency were Schisandra chinensis (103 times, 17.20%), Ophiopogon japonicus (40 times, 6.68%), Poria cocos (40 times, 6.68%), Astragalus membranaceus (39 times, 6.51%). Among the statistics of the tetra qi, warm drugs (85 times, 39.34%) and cold drugs (76 times, 35.19%) accounted for a larger proportion. In the five flavors, sweet (104 times, 30.32%),bitter (97 times, 28.27%) and acrid (84 times, 24.49%) ccount for a large proportion. Meridians of the liver (123times, 22.28%), lung (84 times, 15.22%) and kidney (81 times, 14.67%) were the most common. In addition, combined with the comprehensive analysis of major therapeutic diseases such as palpitation and insomnia, the combination of Schisandra chinensis and tonic deficiency medicine (52 times, 30.95%), Ophiopogon japonicus and Astragalus membranaceus has the highest frequency, and the clinical application is mostly in the form of solid preparations such as pill and tablet. Conclusion: Chinese patent medicine preparation containing Schisandra chinensis is often used together with nourishing deficiency drug, heat-clearing drug, relieving phlegm and relieving cough and asthma drug. The most compatible drugs are liver meridian, kidney meridian, bitter, sweet, partial warm, cold medicine.

Keywords


Schisandra chinensis, Medicine law, Data mining, Proprietary Chinese medicine, Association rules.


DOI
10.12783/dteees/gmee2018/27451

Full Text:

PDF

Refbacks

  • There are currently no refbacks.